Bayer reinforced its commitment to advancing healthcare solutions for patients in the APAC region with very diverse healthcare landscapes and varying patient needs.
‘By 2050, heart failure cases in the Asia-Pacific region are projected to reach 74.5 million, a staggering 127.6% increase from 2025,’ stated Ashraf Al-Ouf, Head of Pharmaceutical Commercial Operations markets in Asia-Pacific at Bayer. ‘Amid these concerning projections, we are poised to address healthcare needs and bring new therapeutic options for patients across countries in East Asia, South Asia, Southeast Asia, and Oceania.’ In addition to Cardiovascular Diseases, Bayer is well positioned to tackle a range of healthcare challenges. Its product portfolio for the APAC markets includes therapies in areas such as Oncology, Ophthalmology, Women’s Health, and Radiology.
In addition, the company is accelerating its momentum through pharmaceutical innovation and clinical research. Currently, Bayer is conducting 34 ongoing clinical trials in APAC, demonstrating its dedication to advancing medical research and improving patient outcomes. Besides, the company has established two life science incubators in Asia: Bayer Co.Lab Kobe and Bayer Co.Lab Shanghai, which is the largest co-creation incubator in APAC. They are focused on fostering and promoting early-stage biotech innovation in areas such as Cell and Gene Therapy and Oncology.
Looking ahead, the APAC markets present significant growth potential for the company. ‘Bayer is leveraging its global expertise while adapting to local market dynamics in Asia- Pacific’, said Ashraf Al-Ouf, Head of Pharmaceutical Commercial Operations for markets in Asia-Pacific at Bayer. ‘We are investing in partnerships and collaborations with local partners that enhance our reach and effectiveness in delivering innovative solutions.’
‘Our research aims to provide a transformative therapeutic option for patients living with congestive heart failure’, explained Gustavo Pesquin, CEO of Asklepios BioPharmaceutical, Inc. (AskBio), Bayer’s wholly owned, independently operated subsidiary. ‘We work relentlessly to reshape what’s possible for those impacted by this severe diagnosis.’
After the first investments into the technologies, Bayer’s drug development pipeline in cell and gene therapies grew and comprises several programs in preclinical, early, and advanced clinical stages. In addition to cardiovascular diseases, key research areas in cell and gene therapies include Neurology, Rare Diseases, and Ophthalmology. This year, Bayer is advancing progress for patients with Parkinson’s disease, being the first company with both investigational cell as well as gene therapies for this condition. More precisely, the investigational gene therapy, currently in clinical Phase II, has received Regenerative Medicine Advanced Therapy designation from the Food and Drug Administration (FDA). The investigational cell therapy, which has also received this designation, is recruiting first patients in a Phase III clinical study. Australia has been included as one of the countries in Asia-Pacific in the clinical Phase III trial. Furthermore, Bayer has recently achieved a significant milestone with the FDA’s Fast Track designation for an investigational cell therapy targeting specific forms of inherited retinal diseases. It is the first clinical study using induced pluripotent stem cell-derived photoreceptor cells to restore vision for these patients by replacing damaged retinal cells with healthy ones.
In addition to its activities in cell and gene therapies, Bayer is driving different modalities across disease areas such as Cardiovascular, Oncology, Women’s Health, Radiology, and Ophthalmology. By advancing its portfolio of innovative products, Bayer remains committed to improving the lives of various patient groups around the world. Of note is Bayer’s recent pipeline progress: submitting a new low dose magnetic resonance imaging (MRI) contrast agent for marketing authorization in several countries worldwide; receiving the first approvals for a hormone-free treatment to relieve moderate to severe vasomotor symptoms in menopausal women; and providing a new treatment option for patients with advanced prostate cancer.
Aligned with its mission ‘Health for all, Hunger for none’, Bayer remains dedicated to shaping the future of healthcare through innovation, investment, and a steadfast commitment on improving patient outcomes in the Asia-Pacific region and across the world.